The company said, "Adaptive Biotechnologies reiterates full year 2023 revenue to be in the range of $205 million to $215 million. We continue to expect operating expenses, including cost of revenue, to be below full year 2022 operating expenses of $385.5 million."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADPT:
- Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
- Adaptive Biotechnologies to Participate in the BofA Securities 2023 Healthcare Conference
- Adaptive Biotechnologies jumps 4% after announcing Takeda partnership
- Adaptive Biotechnologies Announces Translational Collaboration with Takeda to Measure Minimal Residual Disease with Its clonoSEQ® Assay Across Its Hematologic Malignancy Pipeline
- Adaptive Biotechnologies announces translational collaboration with Takeda
